Canada Candle

Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing off-the-shelf, multimodal viral immunotherapies for the treatment of solid tumors. The company's proprietary technology platforms utilize genetically modified adenovirus and herpes simplex virus (HSV) to induce immunogenic cell death and stimulate a systemic, durable immune response against cancer. Its lead candidate, CAN-2409, is currently in Phase 3 clinical trials for localized prostate cancer and Phase 2 trials for non-small cell lung cancer and pancreatic cancer. Candel is also advancing CAN-3110 for recurrent high-grade glioma and leverages its enLIGHTEN Discovery Platform to identify and develop next-generation immunotherapy candidates.